Company intelligence / Profile preview

Issolabi

Ownership: Private
Development stage: Other

Overview

Issolabi is an early-stage biotechnology company focused on the discovery and development of novel small molecule therapeutics for oncology and inflammatory diseases. The company utilizes a proprietary drug discovery platform designed to identify and optimize candidates against challenging biological targets. While currently in the pre-clinical stage, Issolabi aims to advance a pipeline of high-potency compounds toward clinical validation. The firm operates with a focus on precision medicine to address significant unmet needs in complex disease areas.

Therapeutic areas: OncologyImmunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Issolabi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Issolabi.

Explore the full profile